MetaCap

Retension Pharmaceuticals (RTSN) vs Tiziana Life Sciences (TLSA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Retension Pharmaceuticals is the larger company by market cap ($87.6 million vs $79.5 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

RTSN-0.19%TLSA-47.85%
+60%+1%-57%
Oct 9, 20261 yearNov 20, 2026
RTSN-0.19%TLSA-47.85%
+50%-4%-57%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

RTSN versus TLSA key metrics
MetricRTSNTLSA
Share price$10.51$0.6206
Market cap$87.57M$79.45M
1-day change-19.22%-8.14%
YTD return—-58.35%
1-year return—-64.33%
5-year return—-52.98%
EPS (TTM)$-2.61$-0.21
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-11.86M
52-week high$18.64$1.90
52-week low$9.23$0.55
Distance from 52-week high-43.62%-67.34%
Analyst consensusstrong_buynone
Avg. price target upside+391.63%+1203.58%
Average volume144.93K606.04K
Shares outstanding8.33M128.03M
Employees1210
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Retension Pharmaceuticals

RTSN stock →

Retension Pharmaceuticals, Inc. operates as a clinical -stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

About Tiziana Life Sciences

TLSA stock →

Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees

RTSN vs TLSA FAQ

Which is bigger, Retension Pharmaceuticals or Tiziana Life Sciences?

Retension Pharmaceuticals (RTSN) is larger, with a market capitalization of $87.57M compared with $79.45M for Tiziana Life Sciences (TLSA).

Are Retension Pharmaceuticals and Tiziana Life Sciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons